Status:

NOT_YET_RECRUITING

Safety and Efficacy of Remote Ischemic Conditioning in Patients With Spontaneous Intracerebral Hemorrhage

Lead Sponsor:

Yi Yang

Conditions:

Intracranial Hemorrhages

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to determine whether treatment with remote ischemic conditioning is of sufficient promise to improve outcome before conducting a larger clinical trial to examine its effec...

Detailed Description

Intracerebral hemorrhage is a devastating disease with a high rate of severe disability and death, while no specific treatment has been proven to improve functional outcome. As a result, new approache...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years
  • Supratentorial intracerebral hemorrhage confirmed by brain CT scan
  • Functional independence prior to ICH, defined as pre-ICH mRS ≤ 1
  • NIHSS score ≥ 4 and GCS ≥ 6 upon presentation
  • Able to commence RIC treatment within 12 hours of stroke onset
  • Signed and dated informed consent is obtained.

Exclusion

  • Definite evidence of secondary ICH, such as structural abnormality, brain tumor, thrombolytic drug, and other causes
  • A very high likelihood that the patient will die within the next 24 hours on the basis of clinical and/or radiological criteria
  • Already booked for surgical treatment
  • Life expectancy of less than 90 days due to comorbid conditions
  • Severe hematologic disease
  • Concurrent use of anticoagulation drugs including Warfarin, dabigatran, rivaroxaban.
  • Concurrent use of glibenclamide or nicorandil
  • Any soft tissue, orthopedic, or vascular injury, wounds or fractures in healthy upper limb which may pose a contraindication for application of RIC
  • Severe hepatic and renal dysfunction
  • Platelet count \<100×10\^9/L
  • Coagulopathy defined as INR,APTT,and PT beyond the upper limit of normal range
  • Known pregnancy, or positive pregnancy test, or breastfeeding
  • Patients being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial
  • A high likelihood that the patient will not adhere to the study treatment and follow up regimen
  • Patients unsuitable for enrollment in the clinical trial according to investigators decision making.

Key Trial Info

Start Date :

March 15 2026

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 15 2027

Estimated Enrollment :

530 Patients enrolled

Trial Details

Trial ID

NCT03484936

Start Date

March 15 2026

End Date

June 15 2027

Last Update

October 2 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

First Hospital of Jilin University

Changchun, Jilin, China, 130000